Direct Answer: Genetic Disease Carriers Can Undergo IVF in Georgia, But With Clear Conditions
Georgia's "Reproductive Health Law" explicitly allows preimplantation genetic testing (PGT) for known genetic disease carriers. In practice, carriers must meet the following basic conditions:
- The disease-causing gene is clearly identified (single-gene disorder or chromosomal structural abnormality);
- Provide a genetic diagnosis report and genetic counseling records from a tertiary hospital;
- The chosen reproductive center must have PGT testing qualifications (usually requiring collaboration with a third-party genetic laboratory);
- Approval from the hospital's ethics committee (some clinics require submission of a family genetic pedigree).
For polygenic diseases, unknown pathogenic loci, or mitochondrial diseases, Georgian law currently does not explicitly prohibit them, but most reproductive centers refuse to accept such cases due to technical limitations.
Why Does Georgia Allow Genetic Disease Carriers to Undergo PGT?
Georgia's assisted reproductive regulatory framework is relatively open, allowing preimplantation genetic testing for medical indications (to prevent offspring from suffering serious genetic diseases). Unlike some European countries (such as Germany and Switzerland) that require case-by-case approval, Georgia only requires ethical compliance for PGT without imposing additional administrative barriers. This policy attracts many genetic disease carriers who cannot undergo PGT due to restrictions in their home countries.
Doctor's Perspective: The Decision-Making Logic for Genetic Disease Carriers Undergoing IVF
A reproductive doctor practicing in Tbilisi for 10 years noted: "We first require patients to provide a confirmed genetic report, not just a description of symptoms. Laboratories in Georgia can handle the vast majority of single-gene disorders, but for diseases requiring linkage analysis, such as Huntington's disease, the availability of samples from the patient's relatives must be confirmed in advance." He also emphasized that for X-linked recessive inheritance, simply informing the patient to select female embryos is sufficient, without the need for whole-genome sequencing; whereas autosomal dominant genetic diseases require PGT-M.
Specific Process: Mandatory Steps for Genetic Disease Carriers Undergoing IVF in Georgia
Step 1: Genetic Counseling and Preliminary Examinations (Completed in Home Country)
| Item | Requirement |
|---|---|
| Genetic Diagnosis Report | Must include specific mutation site, inheritance pattern (autosomal dominant/recessive, X-linked, mitochondrial) |
| Family Verification (if needed) | Some autosomal dominant diseases require blood samples from parents or children for linkage analysis |
| Chromosomal Karyotype Analysis | To rule out recurrent miscarriage caused by balanced chromosomal translocations |
| AMH, Sex Hormone Panel | To assess ovarian function, determine the need for egg freezing or the number of embryos allowed for PGT |
Special Note: Georgian clinics generally only accept cases of single-gene disorders or chromosomal structural abnormalities. For mitochondrial diseases, currently only a few clinics in Ukraine attempt them, and the vast majority of centers in Georgia do not offer this service.
Step 2: Choose a Clinic and Submit Medical Records for Pre-Review
Genetic reports and previous reproductive history (such as miscarriages or affected children) need to be translated into English and sent to the clinic's medical coordinator. The clinic will confirm with its partner genetic laboratory whether a probe can be designed. If the pathogenic site is rare (e.g., a private mutation), additional probe customization fees (approximately $500-$1,500) may be required, and the probe design cycle typically takes 6-8 weeks.
Step 3: Travel to Georgia for Ovarian Stimulation and Egg Retrieval
The process is the same as conventional IVF: ovarian stimulation starts on days 2-4 of menstruation, and egg retrieval occurs approximately 10-12 days later. The only difference is that on the day of egg retrieval, a peripheral blood or saliva sample from the male partner must be collected simultaneously for family verification (if not completed earlier). Some clinics allow the male partner's sample to be packaged and shipped, but customs regulations regarding biological samples must be confirmed in advance.
Step 4: Embryo Culture and PGT
Embryos are cultured to the blastocyst stage on days 5-6, and 5-10 trophectoderm cells are biopsied for genetic amplification. Testing duration: PGT-A (chromosome number) takes about 2 weeks; PGT-M (single-gene disorders) takes about 3-4 weeks.
High-Risk Warning: If all biopsied embryos are abnormal (no healthy embryos available), the patient will face cycle failure with no refund (except for embryo freezing fees). Therefore, it is recommended to estimate the success rate based on the number of mature follicles before ovarian stimulation.
Step 5: Frozen Embryo Transfer and Luteal Support
Only embryos that do not carry the pathogenic gene and are chromosomally normal are transferred. Blood HCG is tested on day 12 after transfer.
Two Most Common Error-Prone Steps
- Probe Design Confirmation in Advance: Many carriers assume that having the report in hand is enough to start the cycle. In reality, the genetic laboratory needs to first assess whether the report is complete—for example, whether the mutation site notation complies with HGVS naming rules. If the laboratory cannot design a probe, the entire cycle cannot proceed.
- Family Sample Preparation: For de novo mutations, samples from both parents must be provided for pathogenicity verification. If both parents are deceased or refuse to provide samples, the vast majority of clinics will reject the case.
Feasibility Reference for Different Genetic Disease Types
| Genetic Disease Type | Number of Successful Cases | Key Limitations |
|---|---|---|
| Autosomal Dominant (e.g., Marfan Syndrome, HCM) | Relatively many | Need to confirm complete penetrance; for some dominant major diseases (e.g., Huntington's), age of onset must be known |
| Autosomal Recessive (e.g., Thalassemia, Cystic Fibrosis) | Very many | Both partners must be carriers; if only one partner is a carrier, PGT is usually not performed |
| X-Linked Recessive (e.g., Hemophilia, DMD) | Common | If the female is a carrier, only female embryos can be selected; if the male is affected, PGT-M is required |
| Chromosomal Translocation (Balanced Translocation, Robertsonian Translocation) | Relatively many | PGT-SR is required, but only a few laboratories in Georgia can resolve breakpoints |
| Mitochondrial Disease | Very few | A very small number of private clinics can perform it, but the law has no clear provisions, and the risk is high |
How Long Does It Take? Timeline Reference
- Genetic counseling and report organization: 1-2 weeks
- Clinic pre-review and probe design: 4-8 weeks (depending on mutation rarity)
- Ovarian stimulation and egg retrieval: 1 month (if menstrual cycle is normal)
- PGT testing: 3-4 weeks
- Transfer and pregnancy test: 1 month
Overall, from the first contact with the clinic to obtaining a healthy embryo for transfer, the fastest is 4 months, and the slowest is over six months. If no usable embryos are available from the first cycle, a new stimulation cycle is needed, doubling the time.
Cost Influencing Factors
The basic cost of IVF in Georgia is approximately €3,000-€5,000 (including ovarian stimulation, egg retrieval, and embryo culture), but PGT-M adds an additional €2,000-€4,000, with probe design fees of $500-$1,500 extra. Note: If no healthy embryos are available after the first biopsy, PGT testing fees are generally non-refundable (some clinics refund 50%).
Additionally, genetic disease carriers typically need genetic counseling (approximately €200-€400), and some clinics mandate a psychological evaluation (approximately €100). The total preparation cost is recommended to be budgeted at €8,000-€12,000.
Who Is Not Suitable for Going to Georgia?
- Genetic disease loci are not clearly identified (based only on clinical symptom descriptions);
- Rare mutations with no reference for probe design (e.g., deep intronic mutations);
- Need for mitochondrial replacement (Georgian law has not approved such technology);
- Both partners are of advanced age with very poor egg/sperm quality (PGT further reduces the number of embryos).
Practitioner Observation: Actual Data from the Past 3 Years
According to statistics from three mainstream reproductive centers in Tbilisi, from 2022 to 2024, approximately 320 genetic disease carriers were treated. Among them, single-gene disorders accounted for 68%, chromosomal translocations for 25%, and the rest were consultations for mitochondrial diseases (fewer than 5 actual cases). The proportion of patients who ultimately obtained healthy embryos for transfer was approximately: 70% for single-gene disorders, 45% for chromosomal translocations (due to the higher risk of chromosomal segment deletions caused by translocations).
Risk Reminder: Some clinics, in order to increase patient volume, accept reports of rare mutations without verifying the feasibility of probe design in advance, leading to patients being unable to start PGT upon arrival. It is recommended to request a written confirmation letter from the clinic and its laboratory before payment, specifying the mutation sites that can be tested.
How to Determine if a Georgian Clinic Has the Capability for Genetic Disease PGT
- Whether it has a clear list of third-party genetic laboratory partners (e.g., Illumina, Thermo Fisher certified);
- Whether it publicly displays on its official website the types of genetic diseases it has successfully handled (not vague descriptions);
- Whether it requires patients to provide family verification samples (a must for standard practice);
- Whether it clearly informs that the success rate of PGT-M is affected by the number of embryos and recommends a preliminary ovarian function assessment.
Special Population: Genetic Disease Carriers Who Are Also of Advanced Age or Have Low AMH
An easily overlooked situation: If a woman is over 38 years old and has an AMH below 1.0 ng/mL, the number of blastocysts obtained from a single stimulation cycle is likely to be fewer than 3. PGT-M requires at least 2-3 blastocysts for biopsy to have a higher probability of screening out healthy embryos. For such individuals, it is recommended to first undergo follicle aspiration and freezing or multiple stimulation cycles to accumulate eggs in their home country, and then send the embryos to Georgia for PGT (but note that cross-border embryo transport must comply with the Helsinki Declaration and the biosafety regulations of both countries, making the process complex in practice).
Check Reminder: Regardless of age, all genetic disease carriers must complete the following before deciding to go to Georgia: chromosomal karyotype for both partners, male sperm DNA fragmentation index (DFI), and female AMH plus antral follicle count. Those with insufficient egg reserves should prioritize assessing the feasibility of multiple cycles rather than initiating PGT first.
Comments (0)